Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) EBITDA (2016 - 2025)

Sanara MedTech's EBITDA history spans 15 years, with the latest figure at $4.7 million for Q4 2025.

  • For Q4 2025, EBITDA rose 15.73% year-over-year to $4.7 million; the TTM value through Dec 2025 reached $12.9 million, up 71.83%, while the annual FY2025 figure was $17.0 million, 85.97% up from the prior year.
  • EBITDA reached $4.7 million in Q4 2025 per SMTI's latest filing, down from $4.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $6.6 million in Q4 2022 to a low of -$3.3 million in Q2 2022.
  • Average EBITDA over 5 years is $793317.2, with a median of $380165.0 recorded in 2023.
  • Peak YoY movement for EBITDA: crashed 225.52% in 2022, then surged 860.87% in 2024.
  • A 5-year view of EBITDA shows it stood at $2.4 million in 2021, then soared by 177.84% to $6.6 million in 2022, then crashed by 93.25% to $448909.0 in 2023, then skyrocketed by 802.87% to $4.1 million in 2024, then rose by 15.73% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for SMTI's EBITDA are $4.7 million (Q4 2025), $4.9 million (Q3 2025), and $2.7 million (Q2 2025).